Elotuzumab as a novel anti-myeloma immunotherapy
Treatment of multiple myeloma has undergone significant change in the last decade with the introduction of new immunomodulatory agents, proteasome inhibitors, and immunotherapeutic approaches. Elotuzumab is a humanized monoclonal antibody targeting CS1, which is a member of the SLAM (Signaling Lymph...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Taylor & Francis Group
2017-08-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2017.1327487 |
| Tags: |
No Tags, Be the first to tag this record!
|